Table 3.
Network meta-analysis for comparison HbA1c changes from baseline, Body weight change from baseline, Percentage of patients achieving HbA1c <7 and Percentage of patients experiencing hypoglycemic events between 2 groups (If in Table 2 pairs (1 similar 3) & (2 similar 4))
| Comparison | Drug1 | Drug2 | HbA1c change from baseline | Body weight change from baseline | Percentage of patients achieving HbA1c <7% | Percentage of patients experiencing hypoglycemic events | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Freq | Mean difference (SE) | p-value | Freq | Mean difference (SE) | p-value | Freq | Ln(OR) (SE) | p-value | Freq | Ln(OR) (SE) | p-value | |||
| Direct (7) | Linagliptin 5 mg | placebo | 12 | −.495(.119) | 0 | 7 | −0.211(.701) | 0.764 | 9 | 0.711 (.257) | 0.006 | 10 | −1.250 (.271) | 0 |
| Direct (8) | Sitagliptin 100 mg | placebo | 20 | −.375(.072) | 0 | 11 | −0.664 (.553) | 0.229 | 13 | 0.514 (.209) | 0.014 | 19 | −0.753 (.228) | 0.001 |
| Indirect (9) | Linagliptin 5 mg | Sitagliptin 100 mg | – | −0.12(.139) | >.05 | – | 0.454 (.893) | >0.05 | – | 0.197 (.332) | >.05 | 4 | −0.497(.354) | >0.05 |